Available online www.jsaer.com

***Journal of Scientific and Engineering Research*, 2023, 10(12):173-179**

Research Article

ISSN: 2394-2630
CODEN(USA): JSERBR

The Synergy of AI and Human Expertise in Clinical Research: A Path to Optimized Medical Reviews

Aditya Gadiko

Product Management, Saama Technologies, 900 East Hamilton Avenue, Campbell, 95008, CA, USA
Email: aditya.gadiko@saama.com

Abstract The integration of Artificial Intelligence (AI) with human expertise in clinical research promises a revolutionary shift in medical reviews, enhancing efficiency, data integrity, and patient safety. This paper explores the synergy between AI and human expertise, focusing on optimizing medical re- view processes in clinical trials. We highlight the challenges of increasing data volume and complexity, increasing complexity of data issues, pattern recognition, and data analysis, including multimodal data integration. Key to our discourse is the col- laborative model between AI systems and medical professionals. We argue that human judgment and AI's analytical prowess are complementary, offering a balanced approach to Medical data review. This synergy, supported by continuous feedback loops for AI refinement, ensures the precision and reliability of clinical trial outcomes. Ethical considerations, particularly regarding data accuracy, patient privacy, and bias, are addressed by recommending transparency, human oversight, and clear operational guidelines. We conclude that the future of clinical trials hinges on the effective partnership between AI and human expertise, significantly advancing clinical research goals. This paper presents a concise blueprint for leveraging AI in clinical trials, underscoring its potential to redefine medical review standards and improve healthcare outcomes.

1. Introduction

A Medical Monitor is a pivotal figure in clinical trials, endowed with the duty to ensure the safety and well-being of participants throughout the study's course. The breadth of their expertise encompasses direct oversight during the trial's conduct, from its inception in study design to the meticulous close-out phase. As custodians of trial integrity, they serve as a beacon for study teams and investigative sites, offering guidance on interpreting and managing safety events within the clinical spectrum of the trial [1] [2].

The role of a Medical Monitor is central to the governance of clinical trial integrity, where the medical data review process is paramount. This rigorous activity encompasses the formulation and scrutiny of study protocols, clinical narratives, investigator brochures, informed consent forms, and a range of safety documentation, including adverse event reports and mitigation plans. The thoroughness of medical review is vital, standing as the bulwark to safeguard patient welfare through- out the clinical investigation [1]. The proliferation of medical knowledge has seen a remarkable acceleration; estimations assert a doubling time from 50 years in 1950, reduced to 7 years by 1980, and further to a mere 3.5 years by 2010. In 2020, the doubling time of medical knowledge had diminished drastically to 0.2 years—equivalent to approximately 73 days [3]. Parallel to this rapid expansion of knowledge is the exponential growth in data volume, coupled with an increase in the complexity of clinical trials, presenting both challenges and opportunities in medical research [4].

2. Evolving Challenges in Clinical Trial Medical Reviews

In the realm of clinical research, the medical review process is confronted with a multiplicity of challenges, compounded by the dynamic evolution of industry practices. Conventional manual processes, which are inherently time-intensive and prone to inefficiencies, obstruct the effective management of escalating data complexity. As datasets expand, the susceptibility to human error and subsequent inaccuracies correspondingly increases [5], potentially overwhelming research teams and impeding the prompt discernment of data anomalies—imperative for the monitoring of patient safety.

Complicating the landscape further, the development of study protocols is undergoing rapid transformation. Influenced by the rapid advancements in data science and precision medicine, especially in oncology, contemporary study designs have transcended traditional clinical measurements and end- points, now embracing a broader spectrum including wear- able [6], behavioral [7], patient-generated health data [8] and genomic data [9]. Such expansive data collection necessitates that researchers have unfettered access to data, ensuring real-time interaction and analysis to safeguard patient safety and appraise clinical trial progression effectively. The globalization of clinical trials further accentuates the need for uniform review processes, as a diversified and representative patient cohort becomes indispensable [10]. This expansion mandates a homogenized approach to reviewing across disparate patient groups and data assemblages, ensuring consistency and integrity in multi-national research endeavors.

3. Navigating Data Complexity in Clinical Research

Within the pharmaceutical sector, the escalating pace and intricacy of clinical trial execution are well-acknowledged realities. Traditional clinical trial frameworks, typically characterized by single or double arm studies, have been progressively supplanted by multifaceted designs [11] aimed at harnessing a diverse array of data sources. This shift over the preceding decade signifies a departure from convention and ushers in complexities that challenge the efficacy of clinical development groups, particularly those operating in tandem with research hospitals and clinics. The criticality of resource allocation and scalability comes to the fore, propelling the imperative to amplify the research teams' productivity amid a competitive landscape rife with concurrent trials vying for identical resources [12].

Medical reviewers, ensconced at the confluence of data veracity and clinical trial progression, must swiftly discern emergent data trends to pre-empt and address potential risks associated with the proliferation of complex trials. This necessitates the adoption of contemporary methodologies for enhanced data acquisition, review, and purification. Beyond the realm of ongoing data cleansing, medical review teams are tasked with a constellation of pivotal duties, including but not limited to, the vigilant monitoring of safety reports and engaging with study investigators for follow-ups — tasks that emanate from the meticulous analysis of purified datasets. Some of the high-level challenges are presented in Figure 1.

To navigate this landscape with alacrity, the deployment of AI-driven solutions, meticulously engineered for the nuances of clinical research, is posited as a viable pathway. Such technologies promise to streamline the data review and cleansing operations, thereby catalyzing the efficiency and accuracy of medical review teams within the pharmaceutical research milieu.

4. Applications of Artificial Intelligence in Clinical Trials

Artificial Intelligence (AI) is revolutionizing the field of clinical research by introducing capabilities that extend far beyond traditional analytical methodologies. In the design phase of studies, AI algorithms can predict patient enrollment patterns [13] and outcomes [14], leading to more efficient study designs and potentially reducing trial durations. AI models can predict clinical drug response to significantly reduce clinical study sizes and improve clinical trial performance [15]. Moreover, AI excels in its capacity to parse through extensive datasets, identifying patterns and anomalies with speed and precision that human reviewers may not replicate. For instance, machine learning models can detect subtle correlations between patient characteristics and treatment responses, thereby enhancing the understanding of drug efficacy and safety [16]. AI systems are also adept at monitoring real- time data streams from clinical trials, offering the potential to identify adverse events promptly [17], which is crucial for patient safety.

AI's utility in clinical trials also extends to image analysis, where deep learning algorithms analyze medical images to detect pathologies, sometimes even before they are clinically apparent [18]. This capability is particularly transformative in oncology trials, where early detection of tumor response can dictate the course of treatment. Furthermore, natural language processing, a subset of AI, is utilized to extract meaningful insights from unstructured clinical notes [19] and literature, thereby facilitating the synthesis of vast amounts of research findings into actionable intelligence.

AI also holds promise in the operational aspects of clinical trials. It can streamline the management of trial sites, monitor compliance with regulatory standards, and even predict trial risks based on historical data, enabling proactive mitigation strategies [20]. The integration of AI in the management of supply chains for clinical trials is another emerging application, ensuring the timely availability of trial materials and optimizing logistics based on predictive modeling.

In summary, AI's applications in clinical trials are multi- faceted, offering enhancements in study design, patient recruitment, data analysis, image interpretation, literature synthesis, and operational logistics. This technology stands as a pivotal tool in the modernization of clinical research, promising to improve trial efficacy, accelerate drug development, and ultimately advance patient care.

5. Artificial Intelligence in Medical Reviews

Artificial Intelligence (AI) catalyzes the workflow optimization of medical monitors, clinical scientists, and data managers. The deployment of AI can substantially streamline clinical data cleaning, enabling the swift excision of inaccuracies and the reconciliation of datasets. Complex data analysis, an endeavor traditionally marked by its laborious nature, is accelerated by AI's advanced computational capabilities, which can rapidly parse through and interpret multifaceted data structures [21].

Moreover, AI's proficiency in natural language processing allows for crafting customized data listings, enhancing the accessibility and comprehensibility of clinical trial data. Through these applications, AI expedites the workflow and augments the accuracy and depth of clinical data analysis, yielding efficiencies that have transformative implications for the pace and quality of clinical research.

Accelerate Data Cleaning - In clinical research, AI stands at the forefront of innovation, offering a robust solution for managing and analyzing extensive clinical data. Medical Monitors harness AI to process and scrutinize many data points, enabling the immediate identification of patterns and anomalies. This capability to offer timely recommendations based on analytical findings underscores AI's transformative potential in medical review processes. While traditional data cleaning necessitates laborious manual oversight, often leading to a propensity for error as data volumes swell [22], AI systems excel in mitigating these errors through enhanced pattern recognition and anomaly detection [23]. This proficiency ensures that data quality checks are more accurate, streamlining the verification process of study procedures and assessments and adhering to stringent protocol requirements. The incorporation of AI in the early stages of data review and cleaning translates into a substantial reduction in the delay of critical study milestones; for example, Saama Technologies was able to bring down the average time to identify, review, and query a data issue from 27 minutes when done manually to 3 minutes using AI (as shown in Figure 2). By preempting data inconsistencies, AI allows for timely remediation well before the medical review phase, thereby minimizing the risk of prolonged dataset locking and associated delays in study completion and reporting.



Figure 1: Manual Medical Review processes hinder quality



Figure 2: AI vs Traditional Data Review from [32]

AI's utility extends beyond error correction, identifying unexpected patient trends or variations in study adherence that may elude conventional analysis. Moreover, in global or multi-center trials, AI's ability to homogenize disparate datasets ensures uniformity and coherence in data interaction for reviewers, regardless of the diversity in data origin or format.

Perhaps one of AI's most salient attributes is its capacity for self-improvement [24]. With each dataset processed [25], AI algorithms refine their accuracy, progressively enhancing the efficiency of the data-cleaning process. This iterative learning ensures that AI solutions become more adept over time, perpetually elevating the standard of data integrity and fostering a more streamlined and effective framework for medical reviews in clinical trials.

Navigating Data Complexity - The escalation in the volume and intricacy [26] of clinical data necessitates sophisticated approaches to medical review, particularly within the sphere of oncology research. Here, the advent of novel therapeutic strategies, encompassing an array of chemotherapies, targeted agents, and immunotherapies, contributes significantly to the complexity of data [27]. Oncological studies that employ tumor-agnostic approaches or integrate an array of cancer biomarkers yield data of considerable complexity.

These datasets often include distinct subsets of patient data, necessitating nuanced analysis to discern pertinent trends.

Artificial Intelligence (AI) emerges as an indispensable tool in this context, endowed with the capacity to process and dissect vast datasets efficiently. It facilitates the integration of disparate data sources, from electronic health records to sensor-generated data from wearables and routine lab tests, synthesizing them into a comprehensive narrative. Through Natural Language Processing (NLP), AI algorithms can extract salient points from unstructured data sources such as patient notes and clinical observations, converting narratives [28] into actionable insights.

Beyond mere processing, AI has the proficiency to intuitively present complex data through dynamic

dashboards, offering real-time visibility into trends, anomalies, and critical areas of interest, thus enabling researchers to make timely decisions. AI's predictive analytics are crucial in identifying atypical patterns or values within datasets, such as abnormal lab results, and flagging these for immediate review. This prompt detection is essential for early intervention and the assurance of patient safety, particularly in the identification of potential drug-related toxicities.

The ability of AI systems to prioritize data based on relevance and significance alleviates the cognitive load on medical review teams, presenting them with refined, pertinent information. This streamlining of data enables a more focused review process, freeing medical professionals to allocate their expertise where it is most needed, thereby enhancing the efficiency and manageability of clinical trials.

6. Human in The Loop (Hitl)



Figure 3

Artificial Intelligence (AI) serves as an adjunct to the capabilities of medical review teams in processing substantial quantities of intricate study data, but it does not supplant the invaluable expertise of seasoned medical review professionals. The judicious integration of AI into the medical review process not only augments the effectiveness of data analysis but also propels the professional function of medical reviewers to new heights.

To harness AI's full potential while preserving the essential human element, certain best practices are recommended for a synergistic AI-human interface:

Human Oversight: AI operates under the guidance of medical reviewers, whose experiential knowledge of clinical research nuances is indispensable. Such oversight ensures that AI-generated insights are tethered to clinical veracity.

Continuous Training: The iterative feedback from human users is pivotal for the evolution of AI models [29], enhancing their congruity with the dynamic landscape of research objectives, regulatory frameworks, and the nuanced needs of the research team.

Decision Support: AI excels as a decision-support tool, providing researchers with data-driven insights and recommendations [30]. Nevertheless, the ultimate adjudication remains the prerogative of medical reviewers, who interpret and apply the data with authoritative discretion.

Collaborative Evolution: The efficacy of AI is predicated on its collaborative evolution alongside human expertise. As clinical trials burgeon in complexity, the need for AI to assimilate clinical nuances becomes paramount, necessitating continual model refinement and user training.

Figure 3 presents a real-world example of keeping humans in the loop. In it, a medical reviewer is presented with a potential data issue by AI and is provided with the context and 3 options. The notion that AI might displace human roles is a misapprehension in this emerging paradigm. Instead, AI demands human intelligence for its direction and refinement [31]. Those professionals adept at leveraging AI will find their roles and contributions to clinical research increasingly indispensable.

7. Conclusion

As the scope of clinical trials expands, the capacity to gather and scrutinize an unprecedented volume of patient data is augmented. The paramount objective in this evolutionary phase is to harness the entirety of available data to expedite the development of therapies that are both safer and more efficacious, utilizing the leverage afforded by cutting- edge technologies and innovations in process methodologies. Nonetheless, this proliferation of data and diversification of sources introduces a degree of complexity to clinical trials, posing significant challenges for researchers. Constraints on time and resources within pharmaceutical organizations further compound these difficulties.

Artificial Intelligence (AI) is swiftly being recognized as an indispensable instrument in surmounting these challenges, facilitating the attainment of research and development aims within the clinical research arena. AI's prowess in processing vast quantities of data expeditiously positions it as an asset for medical reviewers, enabling them to dedicate greater attention to their principal duties— the review of patient data to ascertain the safety and efficacy of medicinal compounds—rather than becoming mired in the laborious tasks of data aggregation, cleansing, and intricate analysis.

The integration of AI into the medical review process signifies a pivotal transition for clinical researchers, necessitating a shift from conventional manual methods towards more advanced, automated approaches. It is crucial, for the sake of both patient safety and data integrity, that researchers recognize and embrace this transition. By melding AI capabilities with the seasoned expertise of medical reviewers, the industry can effectively confront the data-related challenges that contemporary and forthcoming trials present.

References

[1]. pp. 23–23, 2023. [Online]. Available: https://www.clinicalleader.com/d oc/how-to-make-trials-more-successful-with-medical-monitors-0001

[2]. pp. 25–25, 2023. [Online]. Available: https://vial.com/blog/articles/the role-of-a-medical-monitor-in-clinical-research/

[3]. P. Densen, "Challenges and opportunities facing medical education," Transactions of the American Clinical and Climatological Association, vol. 122, pp. 48–58, 2011.

[4]. M. Causey, pp. 5–5, 2023. [Online]. Available: https://www.acrpnet.or g/2021/05/clinical-trial-complexity-levels-show-unrelenting-increase/

[5]. S. I. Goldberg, A. Niemierko, and A. Turchin, "Analysis of data errors in clinical research databases. AMIA," Annual Symposium proceedings. AMIA Symposium, pp. 242–246, 2008.

[6]. E. S. Izmailova, J. A. Wagner, and E. D. Perakslis, "Wearable Devices in Clinical Trials: Hype and Hypothesis," Clinical pharmacology and therapeutics, vol. 104, no. 1, pp. 42–52, 2018.

[7]. K. Gillies, J. Brehaut, and T. Coffey, "How can behavioural science help us design better trials?" Trials, vol. 22, pp. 882–882, 2021.

[8]. J. Adler-Milstein and P. Nong, "Early experiences with patient generated health data: health system and patient perspectives," J Am Med Inform Assoc, vol. 26, no. 10, pp. 7 647 206–7 647 206, 2019.

[9]. E. Ountzilas, A. M. Tsimberidou, and H. H. Vo, "Clinical trial design in the era of precision medicine," Genome Med, vol. 14, pp. 101–101, 2022.

[10]. F. Thiers, A. Sinskey, and E. Berndt, "Trends in the globalization of clinical trials," Nat Rev Drug Discov, vol. 7, pp. 13–14, 2008.

[11]. J. Orloff, F. Douglas, and J. Pinheiro, "The future of drug development: advancing clinical trial design," Nat Rev Drug Discov, vol. 8, pp. 949– 957, 2009.

[12]. F. H. Cafferty, C. Coyle, S. Rowley, L. Berkman, M. Mackensie, and R. E. Langley, Co-enrolment of Participants into Multiple Cancer Trials: Benefits and Challenges. Clinical oncology (Royal College of Radiologists, Great Britain, 2017. [Online]. Available: https://doi.org/10.1016/j.clon.2017.02.014

[13]. S. M. Meystre, P. M. Heider, and A. Cates, "Piloting an automated clinical trial eligibility surveillance and provider alert system based on artificial intelligence and standard data models," BMC Med Res Methodol, vol. 23, pp. 88–88, 2023.

[14]. S. Askin, D. Burkhalter, and G. Calado, Artificial Intelligence Applied to clinical trials: opportunities and challenges. Health Technol, vol. 13, pp. 203–213, 2023.
[15]. J. D. Jong, I. Cutcutache, M. Page, S. Elmoufti, C. Dilley, H. Fröhlich, and M. Armstrong, "Towards realizing the vision of precision medicine: AI based prediction of clinical drug response," Brain : a journal of neurology, vol. 144, no. 6, pp. 1738–1750, 2021.
[16]. L. K. Vora, A. D. Gholap, K. Jetha, R. R. S. Thakur, H. K. Solanki, and V. P. Chavda, "Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design," Pharmaceutics, vol. 15, no. 7, 1916.
[17]. R. Ball and G. D. Pan, "Artificial Intelligence" for Pharmacovigilance: Ready for Prime Time," Drug safety, vol. 45, pp. 429–438, 2022.
[18]. A. Hosny, C. Parmar, J. Quackenbush, L. H. Schwartz, and H. J. W. L. Aerts, "Artificial intelligence in radiology," Nature reviews. Cancer, vol. 18, no. 8, pp. 500–510, 2018.
[19]. T. Davenport and R. Kalakota, "The potential for artificial intelligence in healthcare," Future healthcare journal, vol. 6, no. 2, pp. 94–98, 2019.
[20]. N. R. Vyas, "Future of risk based monitoring in clinical trials," Int J Clin Trials, vol. 7, no. 3, pp. 221–229, 2020.
[21]. J. Bajwa, U. Munir, A. Nori, and B. Williams, "Artificial intelligence in healthcare: transforming the practice of medicine," Future healthcare journal, vol. 8, no. 2, pp. 188–194, 2021.
[22]. J. V. D. Broeck, S. A. Cunningham, R. Eeckels, and K. Herbst, "Data cleaning: detecting, diagnosing, and editing data abnormalities," PLoS medicine, vol. 2, no. 10, 2005.
[23]. M. Javaid, A. Haleem, R. P. Singh, R. Suman,and S. Rab, "Significance of machine learning in healthcare: Features, pillars and applications," International Journal of Intelligent Networks, 2022.
[24]. M. Chen, P. Zhou, D. Wu, L. Hu, and M. M. Hassan, Atif Alamri, "AI-Skin:Skin disease recognition based on self-learning and wide data collection through a closed-loop framework," Information Infusion, 2020.
[25]. T. Ermolieva, Y. Ermoliev, A. Zagorodny, V. Bogdanov, O. Borodina, P. Havlik, N. Komendantova, and P. Knopov, "Artificial Intelligence, Machine Learning, and Intelligent Decision Support Systems: Iterative "Learning" SQG-based procedures for Distributed Models' Linkage," Artificial Intelligence Journal, vol. 94, no. 2, 2022.
[26]. pp. 12–12, 2023. [Online]. Available: https://www.globenewswire.com/ news-release/2021/01/12/2157143/0/en/Rising-Protocol-Design-Complexity-Is-Driving-Rapid-Growth-in-Clinical-Trial-Data-Volume-According-to-Tufts-Center-for-the-Study-of-Drug-Development.html
[27]. D. V. Catenacci, "Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity," Molecular oncology, vol. 9, no. 5, pp. 967–996, 2015.
[28]. A. Bohr and K. Memarzadeh, "The rise of artificial intelligence in healthcare applications," Artificial Intelligence in Healthcare, pp. 25– 60, 2020.
[29]. D. Sjödin, V. Parida, Palmié, and J. Wincent, "How AI capabilities enable business model innovation: Scaling AI through co-evolutionary processes and feedback loops," Journal of Business Research, pp. 574– 587, 2021.
[30]. M-L How, S-M Cheah, Y-J Chan, A. C. Khor, and E. Say, "Ar- tificial Intelligence-Enhanced Decision Support for Informing Global Sustainable Development: A Human-Centric AI-Thinking Approach," Information, vol. 11, no. 1, pp. 39–39, 2020.
[31]. M. M. M. Peeters, J. V. Diggelen, V. Den, and K. Bosch, pp. 217–238, 2021. [Online]. Available: https://doi.org/10.1007/s00146-020-01005-y
[32]. pp. 2023. [Online]. Available: https://www.saama.com/how-to-use-ai-in-data-management/